NO943915L - Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien - Google Patents

Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien

Info

Publication number
NO943915L
NO943915L NO943915A NO943915A NO943915L NO 943915 L NO943915 L NO 943915L NO 943915 A NO943915 A NO 943915A NO 943915 A NO943915 A NO 943915A NO 943915 L NO943915 L NO 943915L
Authority
NO
Norway
Prior art keywords
lymphocyte activation
activation antigen
immunoglobulin superfamily
disclosed
expressed
Prior art date
Application number
NO943915A
Other languages
English (en)
Norwegian (no)
Other versions
NO943915D0 (no
Inventor
Thomas F Tedder
Liang-Ji Zhou
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of NO943915D0 publication Critical patent/NO943915D0/no
Publication of NO943915L publication Critical patent/NO943915L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO943915A 1992-04-17 1994-10-14 Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien NO943915L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/870,029 US5316920A (en) 1992-04-17 1992-04-17 Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
PCT/US1993/003577 WO1993021318A1 (fr) 1992-04-17 1993-04-14 Antigene hb15 d'activation lymphocytaire appartenant au sous-ordre des immunoglobulines

Publications (2)

Publication Number Publication Date
NO943915D0 NO943915D0 (no) 1994-10-14
NO943915L true NO943915L (no) 1994-12-09

Family

ID=25354648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943915A NO943915L (no) 1992-04-17 1994-10-14 Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien

Country Status (10)

Country Link
US (1) US5316920A (fr)
EP (1) EP0636176B1 (fr)
JP (2) JP3973167B2 (fr)
AT (1) ATE185600T1 (fr)
AU (1) AU685745B2 (fr)
BR (1) BR9306344A (fr)
CA (1) CA2118309C (fr)
DE (1) DE69326759T2 (fr)
NO (1) NO943915L (fr)
WO (1) WO1993021318A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5534430A (en) * 1993-08-31 1996-07-09 Hitachi Chemical Company Limited Cell strain capable of multiplying an Epstein-Barr virus
AU2273397A (en) * 1996-02-15 1997-09-02 Immunex Corporation Methods and compositions for modulating an immune response
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6361939B1 (en) 1996-11-27 2002-03-26 Schering Corporation Isolated mammalian dendritic cell genes; related reagents
WO1998023747A2 (fr) * 1996-11-27 1998-06-04 Schering Corporation Genes isoles de cellules dendritiques de mammiferes et reactifs correspondants
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6210672B1 (en) 1998-10-20 2001-04-03 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce Langerhans cell migration
US7229621B2 (en) 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
WO2003045318A2 (fr) * 2001-11-21 2003-06-05 Celltech R & D, Inc. Manipulation de taux de cytokine au moyen de produits de gene cd83
AU2002950779A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
EP1422241A1 (fr) 2002-11-19 2004-05-26 Alexander Steinkasserer Utilisation des formes solubles des CD83 et acides nucleiques les codant dans letraitement et la prevention des maladies
EP1572976B1 (fr) 2002-11-21 2010-09-15 Celltech R & D, Inc. Modulation de reponses immunitaires
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
JP5570808B2 (ja) 2006-08-18 2014-08-13 アルゴス・セラピューティクス・インコーポレーテッド 併用療法におけるｃｄ８３の使用
US8009721B2 (en) 2007-06-15 2011-08-30 Panasonic Corporation Wireless communication apparatus and response signal spreading method
MX2010012576A (es) * 2008-05-23 2011-04-05 Argos Therapeutics Inc Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso.
WO2014117220A1 (fr) 2013-02-01 2014-08-07 Transbio Ltd Anticorps anti-cd83 et leur utilisation
EP3209695A4 (fr) 2014-10-23 2018-05-30 DendroCyte BioTech Pty Ltd Protéines de liaison cd83 et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2010321C (fr) * 1989-02-21 2004-04-06 Thomas F. Tedder Proteine de surface de cellules associees aux lymphocytes
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
JPH06504186A (ja) * 1990-07-13 1994-05-19 ザ ジェネラル ホスピタル コーポレイション Ｃｄ５３細胞表面抗原とその使用

Also Published As

Publication number Publication date
US5316920A (en) 1994-05-31
JPH09508781A (ja) 1997-09-09
EP0636176B1 (fr) 1999-10-13
BR9306344A (pt) 1998-06-30
CA2118309A1 (fr) 1993-10-28
WO1993021318A1 (fr) 1993-10-28
DE69326759D1 (de) 1999-11-18
ATE185600T1 (de) 1999-10-15
AU4104893A (en) 1993-11-18
CA2118309C (fr) 2000-06-13
JP3973167B2 (ja) 2007-09-12
EP0636176A1 (fr) 1995-02-01
AU685745B2 (en) 1998-01-29
DE69326759T2 (de) 2000-03-02
JP2007159580A (ja) 2007-06-28
NO943915D0 (no) 1994-10-14

Similar Documents

Publication Publication Date Title
NO943915D0 (no) Lymfocyt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien
Kawanaka et al. CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis
Germann et al. Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells
Vercelli et al. Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens.
EP1329459A3 (fr) Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
DK0489837T4 (da) Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
Heusser et al. New concepts of IgE regulation
Samberg et al. Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes
EP0097453A3 (en) Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
Ferrer et al. Differential interleukin secretion by in vitro activated human CD45RA and CD45RO CD4+ T cell subsets
NO862097L (no) Monoklonale antistoffer for humane ikke-smaacelle lungekarsinoma.
Butcher et al. Flow cytometric studies of IL-4-stimulated expression of the CD25 antigen by quiescent human B lymphocyte subpopulations
Pollack et al. Inhibition of antibody-dependent cellular cytotoxicity by autologous lymph node cells
Poros et al. Expression of Helix pomatia (HP) haemagglutinin receptors on cytolytic lymphocytes activated in mixed cultures
Mosmann et al. Heterogeneity of mouse helper T cells and cross-regulation of TH1 and TH2 clones
Ezine et al. Haemopoiesis and early T-cell differentiation
AU6953296A (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Gorczynski et al. Individual‐specific (idiotypic) T‐B cell interactions regulating the production of anti‐2, 4, 6‐trinitrophenyl antibody. I. Generation of suppressor T cells and antibody directed against immunocompetent cells
Trail Canine T lymphocyte subpopulations defined by the expression of IgMFc and IgGFc receptors: factors influencing Fc receptor expression and alterations in T lymphocyte subpopulations in two models of canine disease.
Governa et al. Autoantibodies in 16 patients with extensive burns and a review of the literature
Rhodes‐Feuillette et al. Presence of pH2‐Sensitive Circulating Interferon Among Callithrix jacchus Marmosets
Dong et al. Preliminary report on the clinical application of anti-Jo-1 antibody